Loading clinical trials...

A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy | Clinical Trials | Clareo Health

COMPLETEDPHASE2

A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

A Multicenter, Randomized, Subject-Blind, Investigator-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

NCT03861481•UCB Biopharma S.P.R.L.

View on ClinicalTrials.gov

Summary

The purpose of the study is to evaluate clinical efficacy of rozanolixizumab as a treatment for subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Subject is ≥ 18 years of age with a minimum body weight of ≥42 kg at Visit 1 (Screening)
•Subject has a documented definite or probable diagnosis of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) according to the European Federation of Neurological Societies (EFNS)/ Peripheral Nerve Society (PNS) criteria 2010
•Subject has an immunoglobulin-dependency confirmed by clinical examination during therapy or upon interruption or reduction of therapy within 18 months prior to Screening and documented in medical history
•Subject is on a stable dosage (not more than ±20% deviation) for subcutaneous immunoglobulin (SCIg) or intravenous immunoglobulin (IVIg) and a fixed interval for at least 4 months of either treatment
•Female subjects of childbearing potential must agree to use a highly effective method of birth control, during the study and for a period of 3 months after their final dose of investigational medicinal product (IMP)
•Male subjects with a partner of childbearing potential must be willing to use a condom when sexually active during the study and for 3 months after the final administration of IMP

Exclusion Criteria

•Previously received treatment in this study or subject has previously been exposed to rozanolixizumab
•Current diagnosis or has a history of Type 1 or Type 2 diabetes mellitus and/or hemoglobin A1c level \>6.0 %
•Known immunoglobulin M (IgM)-mediated neuropathy
•Clinical or known evidence of associated systemic diseases that might cause neuropathy or treatment with agents that might lead to neuropathy
•History of clinically relevant ongoing chronic infections
•Family history of primary immunodeficiency
•Received a live vaccination within 8 weeks prior to the Baseline Visit; or intends to have a live vaccination during the course of the study or within 7 weeks following the final dose of IMP
•Received any experimental biological agent within or outside of a clinical study in the past 3 months or within 5 half-lives prior to Baseline
•Prior treatment with rituximab, ofatumumab, or ocrelizumab in the 6 months prior to the Baseline Visit or subject has had prior treatment with rituximab, ofatumumab, or ocrelizumab in the 12 months prior to Baseline and B cells are not within the normal range
•Female subject who is pregnant or lactating

Locations (22)

Cidp01 902

Phoenix, Arizona, United States

Cidp01 905

Los Angeles, California, United States

Cidp01 901

Tampa, Florida, United States

Cidp01 907

Augusta, Georgia, United States

Cidp01 911

Lexington, Kentucky, United States

Cidp01 903

Charlotte, North Carolina, United States

Cidp01 912

Durham, North Carolina, United States

Cidp01 101

Ghent, Belgium

Cidp01 102

Leuven, Belgium

Cidp01 103

Liège, Belgium

Key Dates

Start Date

March 26, 2019

Primary Completion Date

March 31, 2021

Completion Date

March 31, 2021

Last Updated

August 1, 2023

Enrollment

ACTUAL participants

Conditions

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Interventions

Rozanolixizumab

DRUG

Placebo

OTHER

A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

NCT06747351

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

View study

RECRUITING

A Study of HyQvia in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in Routine Clinical Care

NCT06538064

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

View study

COMPLETEDPHASE2

The Evaluation of Efficacy and Safety of Rituximab in Refractory CIDP Patients With IgG4 Autoantibodies

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 1, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions